A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib or Placebo in Advanced Myeloproliferative Disorders and CMML

Trial Profile

A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib or Placebo in Advanced Myeloproliferative Disorders and CMML

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Topotecan
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top